Jinling Pharmaceutical Company Limited manufactures and sells pharmaceutical products in China and internationally. The company offers Mailuoning injection/oral solutions for the treatment of thromboangiitis obliterans, arteriosclerosis obliterans, cerebral thrombosis and sequelae, multiple arteriosclerosis, phlebitis, acute arterial embolism of the limbs, diabetic gangrene, venous thrombosis, and thrombophlebitis, etc., as well as cardiovascular and cerebrovascular diseases; Sulifei ferrous aluminate tablets for the prevention and treatment of iron deficiency anemia; lentinan injection for the adjuvant treatment of malignant tumors; and absorbent gelatin sponges for wound bleeding and trauma hemostasis. It also provides sulfide, silk whitening freckle removal ointment, weidean capsules, and shuling jianpi capsules. In addition, the company offers medical devices; and medical and health care services through hospitals and welfare centers. Further, it engages in medical investment; provision of chemical raw materials, pharmaceutical intermediates, and APIs; elderly care; rehabilitation treatment; psychological counseling; and hospice care activities. Jinling Pharmaceutical Company Limited was incorporated in 1998 and is headquartered in Nanjing, China.
Metrics to compare | 000919 | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship Relationship000919PeersSector | |
|---|---|---|---|---|
P/E Ratio | 145.5x | 21.1x | −0.6x | |
PEG Ratio | −2.22 | 0.59 | 0.00 | |
Price/Book | 1.2x | 2.0x | 2.6x | |
Price / LTM Sales | 1.5x | 3.4x | 3.2x | |
Upside (Analyst Target) | - | 30.6% | 41.8% | |
Fair Value Upside | Unlock | 16.8% | 5.1% | Unlock |